Literature DB >> 32860688

A 2017-2019 Update on Acute Intoxications and Fatalities from Illicit Fentanyl and Analogs.

Pietro Brunetti1, Filippo Pirani1, Jeremy Carlier1, Raffaele Giorgetti1, Francesco Paolo Busardò1, Alfredo Fabrizio Lo Faro1.   

Abstract

The aim of this review was to report the most recent cases of acute intoxication, fatalities and "driving under the influence" cases, involving illicit fentanyl and its newest analogs. When available, information on age, sex, circumstances of exposure, intoxication symptoms, cause of death (if applicable) and toxicology results from biological fluid testing was described. Scientific publications reporting fatalities or acute intoxications involving use of fentanyl derivatives were identified from PubMed, Scopus and institutional/governmental websites from January 2017 up to December 2019. The search terms, used alone and in combination, were as follows: fentanyl, street fentanyl, analogs, compounds, derivatives, abuse, fatality, fatalities, death, toxicity, intoxication and adverse effects. When considered relevant, reports not captured by the initial search but cited in other publications were also included. Of the 2890 sources initially found, only 44 were suitable for the review. Emergent data showed that the most common analogs detected in biological samples and seized materials are acetylfentanyl, acrylfentanyl, butyrfentanyl, carfentanil, cyclopropylfentanyl, fluorofentanyl, 4-fluorobutyrfentanyl, 4-fluoroisobutyrfentanyl, furanylfentanyl, 2-methoxyacetylfentanyl, 3-methylfentanyl and ocfentanil. These compounds were frequently administered in association with other illicit substances, medicinal drugs and/or alcohol; patients and the victims often had a previous history of drug abuse. The trend of fentanyl analogs is rapidly evolving with illicit market fluctuations. Since information about potency and lethal dosage are frequently unknown, it is important to identify the new trends for further investigation on therapeutic use, toxicity and fatal doses, and implement public health measures. Recently marketed fentanyl analogs such as crotonylfentanyl and valerylfentanyl were not involved in intoxications to date, but should be carefully monitored. Many intoxications and fatalities might have gone unnoticed, and research efforts should focus on metabolite identification studies and the implementation of updated and comprehensive analytical methods.
© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 32860688     DOI: 10.1093/jat/bkaa115

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.367


  5 in total

Review 1.  Reports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2017-2020: A Review.

Authors:  Amanda L A Mohr; Barry K Logan; Melissa F Fogarty; Alex J Krotulski; Donna M Papsun; Sherri L Kacinko; Marilyn A Huestis; Jeri D Ropero-Miller
Journal:  J Anal Toxicol       Date:  2022-07-14       Impact factor: 3.220

2.  Interaction With the Lipid Membrane Influences Fentanyl Pharmacology.

Authors:  Katy J Sutcliffe; Robin A Corey; Norah Alhosan; Damiana Cavallo; Sam Groom; Marina Santiago; Chris Bailey; Steven J Charlton; Richard B Sessions; Graeme Henderson; Eamonn Kelly
Journal:  Adv Drug Alcohol Res       Date:  2022-03-21

3.  Synthetic Benzimidazole Opioids: The Emerging Health Challenge for European Drug Users.

Authors:  Annagiulia Di Trana; Simona Pichini; Roberta Pacifici; Raffaele Giorgetti; Francesco Paolo Busardò
Journal:  Front Psychiatry       Date:  2022-03-25       Impact factor: 4.157

Review 4.  Non-fentanyl-derived synthetic opioids emerging during recent years.

Authors:  Koutaro Hasegawa; Kayoko Minakata; Masako Suzuki; Osamu Suzuki
Journal:  Forensic Toxicol       Date:  2022-04-29       Impact factor: 2.541

Review 5.  Designer Benzodiazepines: A Review of Toxicology and Public Health Risks.

Authors:  Pietro Brunetti; Raffaele Giorgetti; Adriano Tagliabracci; Marilyn A Huestis; Francesco Paolo Busardò
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.